Please ensure Javascript is enabled for purposes of website accessibility

Why Vaxart Stock Is Crushing It Today

By Keith Speights – Updated Sep 14, 2020 at 10:43AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA gave a green light for the biotech to begin phase 1 testing of its coronavirus vaccine candidate.

What happened

Shares of Vaxart (VXRT 11.11%) were soaring 20.8% as of 11:22 a.m. EDT on Monday. The huge jump came after the biotech announced Food and Drug Administration clearance to begin a phase 1 clinical trial for Vaxart's oral coronavirus vaccine candidate.

So what

Vaxart reported promising pre-clinical results for its oral COVID-19 vaccine candidate in April. But investors really want to see how the investigational vaccine will work in humans. Thanks to the FDA clearance, they're about to get that opportunity.

Green arrow on a traffic light

Image source: Getty Images.

All of the other novel coronavirus vaccines currently in clinical studies are administered via injection. Vaxart's candidate will be the first vaccine tablet to advance into phase 1 clinical testing.

Should Vaxart's vaccine candidate prove to be safe and effective in human clinical trials, it could have substantial advantages over other coronavirus vaccines. The convenience of administration would be a big plus. Even more important, though, is that Vaxart's oral vaccine doesn't have to be refrigerated, as injectable vaccines do. This means that the company's vaccine would be easier and less costly to transport and store than other COVID-19 vaccines.

Now what

CEO Andrei Floroiu said that the company expects to begin enrollment for the phase 1 study of its oral vaccine candidate this month. It will include healthy adults between the ages of 18 and 55. 

The biotech stock could enjoy another potential catalyst in the near future as well. Vaxart is awaiting results from a nonhuman primate challenge study of its COVID-19 vaccine candidate that's being funded by Operation Warp Speed, the U.S. government program established to accelerate coronavirus vaccine development.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Vaxart, Inc Stock Quote
Vaxart, Inc
$1.30 (11.11%) $0.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.